On August 16, 2023, Diffusion finalized its merger with EIP Pharma and we are now CervoMed.

CervoMed (NASDAQ:CRVO) is a public, Boston, MA-based clinical-stage company focused on developing treatments for degenerative diseases of the brain. For more information about the development pipeline and for CervoMed investor information, please visit: www.cervomed.com

To read more about the merger, please visit the below links:

August 16, 2023 – CervoMed Announces Completion of Merger with EIP Pharma

August 15, 2023 – Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

(This site will automatically redirect on January 1, 2024)
Back to top